BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis
USA - NASDAQ:BMRN - US09061G1013 - Common Stock
54.16 USD
+0.14 (+0.26%)
54.16 USD
0 (0%)
Taking everything into account, BMRN scores 6 out of 10 in our fundamental rating. BMRN was compared to 536 industry peers in the Biotechnology industry. BMRN gets an excellent profitability rating and is at the same time showing great financial health properties. BMRN is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, BMRN could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
BMRN had positive earnings in the past year.
In the past year BMRN had a positive cash flow from operations.
Of the past 5 years BMRN 4 years were profitable.
In the past 5 years BMRN always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.81%, BMRN belongs to the top of the industry, outperforming 93.28% of the companies in the same industry.
With an excellent Return On Equity value of 10.90%, BMRN belongs to the best of the industry, outperforming 93.47% of the companies in the same industry.
The Return On Invested Capital of BMRN (10.27%) is better than 94.22% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BMRN is significantly below the industry average of 16.17%.
The last Return On Invested Capital (10.27%) for BMRN is above the 3 year average (3.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.81% | ||
| ROE | 10.9% | ||
| ROIC | 10.27% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 21.45%, BMRN belongs to the top of the industry, outperforming 94.78% of the companies in the same industry.
BMRN's Operating Margin of 27.07% is amongst the best of the industry. BMRN outperforms 96.08% of its industry peers.
BMRN has a better Gross Margin (79.56%) than 84.89% of its industry peers.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.07% | ||
| PM (TTM) | 21.45% | ||
| GM | 79.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BMRN is still creating some value.
The number of shares outstanding for BMRN has been increased compared to 1 year ago.
BMRN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BMRN has been reduced compared to a year ago.
2.2 Solvency
BMRN has an Altman-Z score of 5.68. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 5.68, BMRN is doing good in the industry, outperforming 77.61% of the companies in the same industry.
The Debt to FCF ratio of BMRN is 0.86, which is an excellent value as it means it would take BMRN, only 0.86 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.86, BMRN belongs to the top of the industry, outperforming 94.96% of the companies in the same industry.
A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.10, BMRN is not doing good in the industry: 63.99% of the companies in the same industry are doing better.
Although BMRN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.86 | ||
| Altman-Z | 5.68 |
ROIC/WACC1.05
WACC9.76%
2.3 Liquidity
A Current Ratio of 5.56 indicates that BMRN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.56, BMRN is in line with its industry, outperforming 59.89% of the companies in the same industry.
BMRN has a Quick Ratio of 3.60. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN has a Quick ratio (3.60) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.56 | ||
| Quick Ratio | 3.6 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 139.01% over the past year.
BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.36%.
Measured over the past years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.86% on average per year.
EPS 1Y (TTM)139.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%119.64%
Revenue 1Y (TTM)18.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%15.92%
3.2 Future
Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.47% on average per year.
BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.65% yearly.
EPS Next Y59.45%
EPS Next 2Y43.31%
EPS Next 3Y34.04%
EPS Next 5Y28.47%
Revenue Next Year12.45%
Revenue Next 2Y10.88%
Revenue Next 3Y9.73%
Revenue Next 5Y7.65%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.07, the valuation of BMRN can be described as correct.
BMRN's Price/Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 95.90% of the companies in the same industry.
BMRN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 11.93 indicates a reasonable valuation of BMRN.
96.64% of the companies in the same industry are more expensive than BMRN, based on the Price/Forward Earnings ratio.
BMRN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.07 | ||
| Fwd PE | 11.93 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 96.46% of the companies listed in the same industry.
BMRN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BMRN is cheaper than 96.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.05 | ||
| EV/EBITDA | 10.21 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BMRN has a very decent profitability rating, which may justify a higher PE ratio.
BMRN's earnings are expected to grow with 34.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.27
PEG (5Y)N/A
EPS Next 2Y43.31%
EPS Next 3Y34.04%
5. Dividend
5.1 Amount
BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
54.16
+0.14 (+0.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.83%
Inst Owner Change-0.35%
Ins Owners0.65%
Ins Owner Change2.1%
Market Cap10.40B
Analysts83.53
Price Target98.18 (81.28%)
Short Float %3.84%
Short Ratio3.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.96%
Min EPS beat(2)31.48%
Max EPS beat(2)44.44%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)4.22%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)18.75%
EPS beat(12)9
Avg EPS beat(12)-3.48%
EPS beat(16)13
Avg EPS beat(16)0.88%
Revenue beat(2)1
Avg Revenue beat(2)2.55%
Min Revenue beat(2)-1.37%
Max Revenue beat(2)6.48%
Revenue beat(4)3
Avg Revenue beat(4)3.05%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.05%
Revenue beat(12)5
Avg Revenue beat(12)0.21%
Revenue beat(16)7
Avg Revenue beat(16)-0.31%
PT rev (1m)-0.62%
PT rev (3m)0.33%
EPS NQ rev (1m)-3.48%
EPS NQ rev (3m)-29.26%
EPS NY rev (1m)0.99%
EPS NY rev (3m)-0.02%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-1.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.97%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.07 | ||
| Fwd PE | 11.93 | ||
| P/S | 3.39 | ||
| P/FCF | 15.05 | ||
| P/OCF | 13.56 | ||
| P/B | 1.73 | ||
| P/tB | 1.86 | ||
| EV/EBITDA | 10.21 |
EPS(TTM)3.37
EY6.22%
EPS(NY)4.54
Fwd EY8.38%
FCF(TTM)3.6
FCFY6.65%
OCF(TTM)3.99
OCFY7.37%
SpS15.96
BVpS31.39
TBVpS29.12
PEG (NY)0.27
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.81% | ||
| ROE | 10.9% | ||
| ROCE | 12.25% | ||
| ROIC | 10.27% | ||
| ROICexc | 13.02% | ||
| ROICexgc | 14.18% | ||
| OM | 27.07% | ||
| PM (TTM) | 21.45% | ||
| GM | 79.56% | ||
| FCFM | 22.56% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score7
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.86 | ||
| Debt/EBITDA | 0.65 | ||
| Cap/Depr | 90.83% | ||
| Cap/Sales | 2.47% | ||
| Interest Coverage | 93.49 | ||
| Cash Conversion | 84.01% | ||
| Profit Quality | 105.16% | ||
| Current Ratio | 5.56 | ||
| Quick Ratio | 3.6 | ||
| Altman-Z | 5.68 |
F-Score7
WACC9.76%
ROIC/WACC1.05
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)139.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%119.64%
EPS Next Y59.45%
EPS Next 2Y43.31%
EPS Next 3Y34.04%
EPS Next 5Y28.47%
Revenue 1Y (TTM)18.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%15.92%
Revenue Next Year12.45%
Revenue Next 2Y10.88%
Revenue Next 3Y9.73%
Revenue Next 5Y7.65%
EBIT growth 1Y198.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year97.49%
EBIT Next 3Y41.32%
EBIT Next 5Y23.56%
FCF growth 1Y1589.89%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y375.67%
OCF growth 3Y23.45%
OCF growth 5Y63.99%